Nothing Special   »   [go: up one dir, main page]

CA2439920A1 - Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol - Google Patents

Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol Download PDF

Info

Publication number
CA2439920A1
CA2439920A1 CA002439920A CA2439920A CA2439920A1 CA 2439920 A1 CA2439920 A1 CA 2439920A1 CA 002439920 A CA002439920 A CA 002439920A CA 2439920 A CA2439920 A CA 2439920A CA 2439920 A1 CA2439920 A1 CA 2439920A1
Authority
CA
Canada
Prior art keywords
patient
absorption inhibitor
effective amount
cholesterol absorption
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439920A
Other languages
English (en)
Inventor
Steven A. Nichtberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439920A1 publication Critical patent/CA2439920A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement de l'athérosclérose et de prévention des maladies athérosclérotiques chez un patient hypertendu. Ces méthodes consistent à administrer au patient une dose thérapeutiquement ou préventivement efficace d'au moins un composé antihypertenseur combinée avec une dose thérapeutiquement efficace d'un inhibiteur de l'absorption du cholestérol. L'invention concerne également une composition renfermant au moins un composé antihypertenseur et un inhibiteur de l'absorption du cholestérol en doses thérapeutiquement efficaces, ainsi qu'un substrat pharmaceutiquement acceptable.
CA002439920A 2001-03-08 2002-03-05 Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol Abandoned CA2439920A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27428801P 2001-03-08 2001-03-08
US60/274,288 2001-03-08
PCT/US2002/006570 WO2002072104A2 (fr) 2001-03-08 2002-03-05 Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol

Publications (1)

Publication Number Publication Date
CA2439920A1 true CA2439920A1 (fr) 2002-09-19

Family

ID=23047586

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439920A Abandoned CA2439920A1 (fr) 2001-03-08 2002-03-05 Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol

Country Status (5)

Country Link
EP (1) EP1389114A2 (fr)
JP (1) JP2004523569A (fr)
AU (1) AU2002336267B2 (fr)
CA (1) CA2439920A1 (fr)
WO (1) WO2002072104A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60224163T2 (de) * 2001-01-26 2008-12-04 Schering Corp. Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
BR0206644A (pt) * 2001-01-26 2004-02-25 Schering Corp Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
SK288217B6 (sk) * 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
DE602004029715D1 (de) 2003-12-23 2010-12-02 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
KR20070063592A (ko) * 2005-09-08 2007-06-19 테바 파마슈티컬 인더스트리즈 리미티드 에제티밉의 합성을 위한 중간체인(3ｒ,4ｓ)-4-((4-벤질옥시)페닐)-1-(4-플루오로페닐)-3-((ｓ)-3-(4-플루오로페닐)-3-히드록시프로필)-2-아제티디논의제조 방법
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
JP2013512199A (ja) * 2009-11-30 2013-04-11 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EA200100704A1 (ru) * 1998-12-23 2002-02-28 Джи.Ди.Сирл Ллс Комбинация для применения по сердечно-сосудистым показаниям

Also Published As

Publication number Publication date
JP2004523569A (ja) 2004-08-05
WO2002072104A3 (fr) 2003-07-24
AU2002336267B2 (en) 2006-10-05
WO2002072104A2 (fr) 2002-09-19
EP1389114A2 (fr) 2004-02-18

Similar Documents

Publication Publication Date Title
JP3883205B2 (ja) アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
CA2241466C (fr) Composition pharmaceutique comprenant un antagoniste de l'angiotensine ii
US8101599B2 (en) Pharmaceutical composition containing anti-hypertensive agents
WO2007106708A2 (fr) Combinaison de composes organiques
CA2904447A1 (fr) Therapie pour complications du diabete
CN101300030A (zh) 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品
AU2002336267B2 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CA2642685A1 (fr) Traitement antihypertenseur
AU2002336267A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2008112167A1 (fr) Combinaison de lipoate de metformine r-(+) et d'agents hypotenseurs pour le traitement de l'hyperglycémie diabétique et des complications du diabète
US20190241545A1 (en) 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury
US20040116510A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CA2973114A1 (fr) Traitement combine pour l'hypertension pulmonaire
ES2213296T3 (es) Uso de un antagonista del receptor de angiotensina ii para la preparacion de medicamentos para aumentar la tasa de supervivencia de pacientes con trasplante renal.
US9545445B2 (en) Therapeutic drug for hypertension or prehypertension
CA2459017A1 (fr) Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
CN102166357A (zh) 包含双环氮杂烷类衍生物的药物组合物
US20080194626A1 (en) Antihypertensive drug combination

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued